Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00280917 · ClinicalTrials.gov registry record · Phase 2

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

A Phase 2 study of Rheumatoid Arthritis, sponsored by Can-Fite BioPharma.

Completed
Registry status
Phase 2
Development phase
254
Enrollment target
20
Study locations

NCT00280917 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Can-Fite BioPharma. The registered enrollment target is 254 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00280917, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Can-Fite BioPharma.

COMPLETED
Registry status
Phase 2
Development phase
254 participants
Enrollment target
20
Study locations

Study Summary

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG CF101

Study Locations (20)

Other

  • Can-Fite Investigational Site - Plovdiv
  • Can-Fite Investigational Site - Sofia
  • Can-Fite Investigational Site - Sofia
  • Can-Fite Investigational Site - Stara Zagora
  • Can-Fite Investigational Sites - Afula
  • Can-Fite Investigational Site - Ashkelon
  • Can-Fite Investigational Site - Beer Yaakov
  • Can-Fite Investigational Site - Haifa
  • Can-Fite Investigational Site - Haifa
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Jerusalem
  • Can-Fite Investigational Site - Kfar Saba
  • Can-Fite Investigational Site - Tel Litwinsky
  • Can-Fite Investigational Site - Bialystok

Ohio

  • Can-Fite Invesitigational Site - Cleveland
  • Can-Fite Investigational Site - Perrysburg

Arizona

  • Can-Fite Investigational Site - Peoria

New York

  • Can-Fite Investigational Site - Albany

Texas

  • Can-Fite Investigational Site - Sugar Land

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2006-06
Est. Completion 2007-04
Phase Phase 2

Sponsor

Can-Fite BioPharma

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00280917

The ClinicalTrials.gov registry entry for NCT00280917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The listed sponsor is Can-Fite BioPharma, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which CF101 is the first listed.

NCT00280917 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Ohio, Arizona.

Frequently Asked Questions

What is clinical trial NCT00280917 about?

NCT00280917 is a clinical study titled "Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients". This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

What is the current status of trial NCT00280917?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2006-06. Estimated completion is 2007-04.

What conditions does trial NCT00280917 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00280917?

The interventions under investigation include: CF101 (DRUG).

Who is sponsoring clinical trial NCT00280917?

This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00280917 being conducted?

This trial has 20 study locations across Arizona, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.